Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Receivables (2016 - 2025)

CV Sciences' Receivables history spans 13 years, with the latest figure at $405000.0 for Q3 2025.

  • For Q3 2025, Receivables fell 4.03% year-over-year to $405000.0; the TTM value through Sep 2025 reached $405000.0, down 4.03%, while the annual FY2024 figure was $522000.0, 21.11% up from the prior year.
  • Receivables for Q3 2025 was $405000.0 at CV Sciences, down from $545000.0 in the prior quarter.
  • Across five years, Receivables topped out at $8.2 million in Q3 2021 and bottomed at $405000.0 in Q3 2025.
  • The 5-year median for Receivables is $666000.0 (2023), against an average of $3.5 million.
  • The largest annual shift saw Receivables skyrocketed 206.11% in 2022 before it plummeted 93.99% in 2023.
  • A 5-year view of Receivables shows it stood at $2.3 million in 2021, then surged by 206.11% to $7.2 million in 2022, then tumbled by 93.99% to $431000.0 in 2023, then rose by 21.11% to $522000.0 in 2024, then dropped by 22.41% to $405000.0 in 2025.
  • Per Business Quant, the three most recent readings for CVSI's Receivables are $405000.0 (Q3 2025), $545000.0 (Q2 2025), and $430000.0 (Q1 2025).